302 related articles for article (PubMed ID: 20164558)
1. Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects.
Verwey NA; Kester MI; van der Flier WM; Veerhuis R; Berkhof H; Twaalfhoven H; Blankenstein MA; Scheltens And P; Pijnenburg YA
J Alzheimers Dis; 2010; 20(2):445-52. PubMed ID: 20164558
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid Aβ40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease.
Baldeiras I; Santana I; Leitão MJ; Ribeiro MH; Pascoal R; Duro D; Lemos R; Santiago B; Almeida MR; Oliveira CR
J Neurol Sci; 2015 Nov; 358(1-2):308-16. PubMed ID: 26388316
[TBL] [Abstract][Full Text] [Related]
3. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration.
Kapaki E; Paraskevas GP; Papageorgiou SG; Bonakis A; Kalfakis N; Zalonis I; Vassilopoulos D
Alzheimer Dis Assoc Disord; 2008; 22(1):47-53. PubMed ID: 18317246
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
[TBL] [Abstract][Full Text] [Related]
7. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau.
Lewczuk P; Esselmann H; Otto M; Maler JM; Henkel AW; Henkel MK; Eikenberg O; Antz C; Krause WR; Reulbach U; Kornhuber J; Wiltfang J
Neurobiol Aging; 2004 Mar; 25(3):273-81. PubMed ID: 15123331
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
9. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration.
Noguchi M; Yoshita M; Matsumoto Y; Ono K; Iwasa K; Yamada M
J Neurol Sci; 2005 Oct; 237(1-2):61-5. PubMed ID: 15992827
[TBL] [Abstract][Full Text] [Related]
10. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
[TBL] [Abstract][Full Text] [Related]
11. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease.
Schoonenboom NS; van der Flier WM; Blankenstein MA; Bouwman FH; Van Kamp GJ; Barkhof F; Scheltens P
Neurobiol Aging; 2008 May; 29(5):669-75. PubMed ID: 17208336
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid biomarkers in Progranulin mutations carriers.
Carecchio M; Fenoglio C; Cortini F; Comi C; Benussi L; Ghidoni R; Borroni B; De Riz M; Serpente M; Cantoni C; Franceschi M; Albertini V; Monaco F; Rainero I; Binetti G; Padovani A; Bresolin N; Scarpini E; Galimberti D
J Alzheimers Dis; 2011; 27(4):781-90. PubMed ID: 21891865
[TBL] [Abstract][Full Text] [Related]
13. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.
Kanai M; Matsubara E; Isoe K; Urakami K; Nakashima K; Arai H; Sasaki H; Abe K; Iwatsubo T; Kosaka T; Watanabe M; Tomidokoro Y; Shizuka M; Mizushima K; Nakamura T; Igeta Y; Ikeda Y; Amari M; Kawarabayashi T; Ishiguro K; Harigaya Y; Wakabayashi K; Okamoto K; Hirai S; Shoji M
Ann Neurol; 1998 Jul; 44(1):17-26. PubMed ID: 9667589
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal stability of CSF biomarkers in Alzheimer's disease.
Blennow K; Zetterberg H; Minthon L; Lannfelt L; Strid S; Annas P; Basun H; Andreasen N
Neurosci Lett; 2007 May; 419(1):18-22. PubMed ID: 17482358
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.
Hansson O; Zetterberg H; Buchhave P; Andreasson U; Londos E; Minthon L; Blennow K
Dement Geriatr Cogn Disord; 2007; 23(5):316-20. PubMed ID: 17374949
[TBL] [Abstract][Full Text] [Related]
18. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease.
Smach MA; Charfeddine B; Ben Othman L; Lammouchi T; Dridi H; Nafati S; Ltaief A; Bennamou S; Limem K
Eur Neurol; 2009; 62(6):349-55. PubMed ID: 19786779
[TBL] [Abstract][Full Text] [Related]
20. CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age.
Kester MI; Blankenstein MA; Bouwman FH; van Elk EJ; Scheltens P; van der Flier WM
J Alzheimers Dis; 2009; 16(3):601-7. PubMed ID: 19276554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
